Nxera Pharma to Cut 15% of Workforce in Japan and UK as Part of Restructuring Plan

Nxera Pharma announced on November 17–18, 2025, that it will cut approximately 15% of its workforce in both Japan and the UK as part of a major restructuring initiative1 3 4 5 6 8.

The restructuring aims to streamline R&D operations and return the company to profitability through operational consolidation, streamlining, and outplacement/early retirement programs1 5.

The workforce reduction initiative is focused on improving operational efficiency, including optimization of selling, general, and administrative (SG&A) functions, and leveraging IT to reduce outsourced services, specifically in Japan and the UK5.

Nxera emphasized that the restructuring is aligned with its new strategic focus on advancing its next-generation GPCR medicines and AI-enabled drug discovery programs6 8.

The initiative will not impact Nxera’s operations in Switzerland and South Korea8.

The company stated that compliance and fairness would be prioritized throughout the restructuring process, which is already underway in both regions5.

Recent R&D progress and anticipated milestones, especially related to the GPCR pipeline and the proprietary NxWave™ platform, remain strategic priorities for the company post-restructuring5.